In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kids, Time To Play Your Medicine: Akili Prepares Launch Of EndeavorRx Video Game For ADHD

Executive Summary

After being first to receive FDA clearance for a prescription-only software to treat ADHD and raising total funding of $230m, Akili plans a US launch in 2022 while targeting other indications.

You may also be interested in...



Gaming For Attention: FDA Grants De Novo For Novel ADHD Treatment

A new video game pediatric ADHD treatment has opened the door for other such novel therapies to come to market using the less stringent 510(k) pathway, as interest in such products have gained significant steam over the past few years.

Expert Panel Discusses Trends In Digital Health Investment

An expert panel at the AdvaMed MedTech Conference in San Francisco discussed trends in digital health investment including market opportunities and regulatory and reimbursement challenges.

Akili Strikes $125m Digital Med Deal With Japanese Partner

PureTech Health's Akili has announced a $125m partnership with Japanese pharmaceutical company Shionogi to commercialize two of its digital therapeutics in Japan and Taiwan.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV124971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel